Challenge to US drug price negotiation program revived by appeals court
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...
An appeals court has revived a challenge to President Biden’s Medicare drug price reduction program
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
Another AZ county joins federal program to combat drug trafficking
Yavapai County will be part of the High Intensity Drug Trafficking Area program, which opens up federal resources to police ...
With TV Drug Ads, What You See Is Not Necessarily What You Get
The U.S. is one of only two countries that legally allows drugmakers to advertise products directly to patients. There are ...
Here’s how Biden is averting a spike in Medicare drug plan premiums
President Joe Biden and Vice President Kamala Harris have repeatedly touted on the campaign trail their efforts to lower drug ...
Quality Assurance5d
FDA Releases Annual Pesticide Residue Monitoring Program for Fiscal Year 2022
The FDA released its annual Pesticide Residue Monitoring Program Report for Fiscal Year 2022, summarizing findings from the ...
FTC Sues Drug Middlemen Over Manipulating Insulin Market
The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing ...
The National Law Review5d
The 340B Drug Pricing Program: Top Five Things to Know
The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ...
Smith, Popovian: Federal drug pricing program is costing taxpayers billions
The federal 340B Drug Pricing Program was designed to encourage hospitals and clinics to provide low-income patients with ...
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...
FierceBiotech4d
FDA scraps adcomm for Applied's rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...